25721902Lucas DM, Ruppert AS, Lozanski G, Dewald GW, Lozanski A, Claus R, Plass C, Flinn IW, Neuberg DS, Paietta EM, Bennett JM, Jelinek DF, Gribben JG, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS, Byrd JC, Grever MRLeukemia & lymphomaAntineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Leukemia, Lymphocytic, Chronic, B-Cell; VidarabineAdult; Aged; Aged, 80 and over; Biomarkers; CpG Islands; Cyclophosphamide; DNA Methylation; DNA Mutational Analysis; Female; Follow-Up Studies; Humans; Immunoglobulin Heavy Chains; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Mutation; Prognosis; Treatment Outcome; ZAP-70 Protein-Tyrosine KinaseCytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. Leuk Lymphoma. 2015; 56(11):3031-7.Leuk Lymphoma2015-03-30T00:00:002015Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000369Living Beings93664810.461294Aged, 80 and overD000368Living Beings1341183530.294764AgedD000328Living Beings1578255770.254432AdultD000971Procedures30624340.476235Antineoplastic Combined Chemotherapy ProtocolsD004252Procedures2265260.864587DNA Mutational AnalysisD003520Chemicals & Drugs1242990.920618CyclophosphamideD007143Chemicals & Drugs431310.959338Immunoglobulin Heavy ChainsD008875Concepts & IdeasLiving Beings1473249570.258811Middle AgedD009154Physiology70239520.442648MutationD005260Physiology1992444050.191167FemaleD006801Living Beings2262862810.130052HumansD015415Concepts & Ideas59717090.619575BiomarkersD015451Disorders571360.907606Leukemia, Lymphocytic, Chronic, B-CellD008297Physiology1931408600.201617MaleD014740Chemicals & Drugs191410.950579VidarabineMedicine-Hematology and OncologyD016896Concepts & Ideas101179490.402389Treatment OutcomeD018899Chemicals & Drugs731500.943268CpG IslandsD017404Procedures1463480.913343In Situ Hybridization, FluorescenceD011379Procedures74536690.561447PrognosisD015999Concepts & Ideas4199970.796631Multivariate AnalysisD019175Physiology1976220.705339DNA MethylationD051746Chemicals & Drugs14180.992054ZAP-70 Protein-Tyrosine KinaseD053208Concepts & Ideas3258590.818599Kaplan-Meier EstimateD002869Disorders1113860.870742Chromosome AberrationsD005500Procedures76836160.590107Follow-Up StudiesUniversity of ChicagoRichard A.LarsonRichard A. Larson41.78927490000000-87.601250000000001169Larson, Richard A.Professortrue1ProfessorProfessorAuthorship 84478160.1340030.1340031authors10.2525has subject area